

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity	SIGMA PHARMACEUTICALS LIMITED
ABN	15 088 417 403

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Mark Robert Hooper
Date of last notice	22/06/2016

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest	Direct								
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.									
Date of change	23/06/2016								
No. of securities held prior to change	<p>34,808,292</p> <table style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 80%;">Ordinary Shares</td> <td style="text-align: right;">6,084,943</td> </tr> <tr> <td>Shares allocated pursuant to the employee share plan</td> <td style="text-align: right;">26,112</td> </tr> <tr> <td>Shares allocated pursuant to the loan funded long term incentive plan</td> <td style="text-align: right;">28,459,560</td> </tr> <tr> <td>Short term incentive plan performance rights</td> <td style="text-align: right;">237,677</td> </tr> </table>	Ordinary Shares	6,084,943	Shares allocated pursuant to the employee share plan	26,112	Shares allocated pursuant to the loan funded long term incentive plan	28,459,560	Short term incentive plan performance rights	237,677
Ordinary Shares	6,084,943								
Shares allocated pursuant to the employee share plan	26,112								
Shares allocated pursuant to the loan funded long term incentive plan	28,459,560								
Short term incentive plan performance rights	237,677								
Class	Ordinary								

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Number acquired	7,500
Number disposed	
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	\$9,000.00
No. of securities held after change	34,815,792 Ordinary Shares 6,084,943 Shares allocated pursuant to the employee share plan 33,612 Shares allocated pursuant to the loan funded long term incentive plan 28,459,560 Short term incentive plan performance rights 237,677
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	7,500 shares allocated pursuant to the employee share plan

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	
Name of registered holder (if issued securities)	
Date of change	
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	
Interest acquired	

+ See chapter 19 for defined terms.

Appendix 3Y
Change of Director's Interest Notice

Interest disposed	
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	
Interest after change	

Part 3 – +Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	No
If so, was prior written clearance provided to allow the trade to proceed during this period?	
If prior written clearance was provided, on what date was this provided?	

+ See chapter 19 for defined terms.